Indeed, a high prevalence of MYD88 L265P (44%) and CD79B (26%) mutations have recently been reported in IVLBCL [50] and in PC DLBCL-LT (70–80% and 40%, respectively) [51,52]. Here, MYD88 is linked to diffuse large B-cell lymphoma.